Dr Reddys Company Insiders
RDY Stock | USD 74.57 0.55 0.74% |
Dr Reddys employs about 25.9 K people. The company is managed by 56 executives with a total tenure of roughly 416 years, averaging almost 7.0 years of service per executive, having 461.84 employees per reported executive. Break down of Dr Reddys' management performance can provide insight into the company performance.
M Ramana CEO Chief Executive Officer, Branded Markets (India and Emerging Markets) |
Satish Reddy Chairman Co-Chairman of the Board |
RDY |
Dr Reddys' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Dr Reddys' future performance. Based on our forecasts, it is anticipated that RDY will maintain a workforce of slightly above 25860 employees by May 2024.Dr Reddys Management Team Effectiveness
The company has Return on Asset of 0.1238 % which means that on every $100 spent on assets, it made $0.1238 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2139 %, implying that it generated $0.2139 on every 100 dollars invested. Dr Reddys' management efficiency ratios could be used to measure how well Dr Reddys manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.38 in 2024, whereas Return On Tangible Assets are likely to drop 0.11 in 2024. At this time, Dr Reddys' Other Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 15.4 B in 2024, whereas Total Assets are likely to drop slightly above 206.1 B in 2024.Net Income Applicable To Common Shares is likely to rise to about 54.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 175.2 M in 2024.
Dr Reddys Workforce Comparison
Dr Reddys Laboratories is currently regarded as top stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 26,515. Dr Reddys totals roughly 25,863 in number of employees claiming about 98% of equities under Health Care industry.
Dr Reddys Profit Margins
The company has Net Profit Margin of 0.19 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.44 | 0.74 |
|
| |||||
Net Profit Margin | 0.12 | 0.21 |
|
| |||||
Operating Profit Margin | 0.37 | 0.35 |
|
| |||||
Pretax Profit Margin | 0.11 | 0.22 |
|
| |||||
Return On Assets | 0.0883 | 0.16 |
|
| |||||
Return On Equity | 0.14 | 0.22 |
|
|
Dr Reddys Laboratories Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Dr Reddys Laboratories Price Series Summation is a cross summation of Dr Reddys price series and its benchmark/peer.
Dr Reddys Notable Stakeholders
A Dr Reddys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dr Reddys often face trade-offs trying to please all of them. Dr Reddys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dr Reddys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MARC KIKUCHI | Chief Executive Officer, North America Generics | Profile | |
Venkata MBA | CEO Council | Profile | |
Patrick Aghanian | Chief Executive Officer, European Generics | Profile | |
M Ramana | Chief Executive Officer, Branded Markets (India and Emerging Markets) | Profile | |
Satish Reddy | Co-Chairman of the Board | Profile | |
G Prasad | Co-Chairman of the Board, Chief Executive Officer, Managing Director | Profile | |
Samiran Das | Executive Vice President Head - FTO and GGPM | Profile | |
Amit Biswas | Executive Vice President - Integrated Product Development | Profile | |
K Rao | Sr. Vice President & Head – Chemical Technical Operations (CTO) | Profile | |
Raghav Chari | Senior Vice President - Proprietary Products | Profile | |
Umang Vohra | Executive Vice President Head - North America Generics | Profile | |
Cartikeya Reddy | Senior Vice President Head - Biologics | Profile | |
Alok Sonig | Senior Vice President & India Business Head (Generics) | Profile | |
J Ramachandran | Executive Vice President-Management Systems and Corporate Initiatives | Profile | |
Saumen Chakraborty | President, Chief Financial Officer and Global Head of ITBPE, Legal and Compliance and FMCRE | Profile | |
Ganadhish Kamat | Executive Vice President and Global Head-Quality | Profile | |
Sripada Chandrasekhar | President, Global Head of HR and Member of Management Council | Profile | |
Parag Agarwal | Chief Financial Officer - Designate | Profile | |
Abhijit Mukherjee | COO | Profile | |
Erez Israeli | Chief Operating Officer and Global Head of Generics & PSAI | Profile | |
Leo Puri | Non-Executive Independent Director | Profile | |
Ravi Bhoothalingam | Non-Executive Independent Director | Profile | |
Prasad Menon | Lead Non-Executive Independent Director | Profile | |
Shikha Sharma | Non-Executive Independent Director | Profile | |
Omkar Goswami | Non-Executive Independent Director | Profile | |
Bharat Doshi | Non-Executive Independent Director | Profile | |
Bruce Carter | Non-Executive Independent Director | Profile | |
Hans Hasler | Additional Independent Director | Profile | |
Allan Oberman | Non-Executive Independent Director | Profile | |
Sridar Iyengar | Non-Executive Independent Director | Profile | |
Kalpana Morparia | Non-Executive Independent Director | Profile | |
J Moreau | Non-Executive Independent Director | Profile | |
Ashok Ganguly | Non-Executive Independent Director | Profile | |
Anupam Puri | Non-Executive Independent Director | Profile | |
Sandeep Poddar | Compliance Officer, Company Secretary | Profile | |
Kedar Upadhye | IR Contact Officer | Profile | |
Sanjay BTech | Global VP | Profile | |
K Krishnan | Additional Independent Director | Profile | |
Gunupati BE | MD CoChairman | Profile | |
Raymond Vre | Global Head of Biologics | Profile | |
Archana Bhaskar | Chief Human Resource Officer | Profile | |
Erez MBA | CEO Council | Profile | |
MS BTech | Chairman Council | Profile | |
Deepak Sapra | Global Head of Pharmaceutical Services and Active Ingredients | Profile | |
Penny Wan | Additional Independent Director | Profile | |
P Yugandhar | Global Head of Supply Chain | Profile | |
Sauri Gudlavalleti | Global Head of Integrated Product Development Organization | Profile | |
YUGANDHAR PUVVALA | Global Head of Supply Chain | Profile | |
K Singh | Chief Compliance Officer, Company Secretary | Profile | |
Anil Namboodiripad | Global Head of Proprietary Products | Profile | |
SANJAY SHARMA | Global Head of Manufacturing | Profile | |
Vivek Mittal | Interim Compliance Officer, General Counsel | Profile | |
Saunak Savla | IR Contact Officer | Profile | |
Deepak MBA | CEO Council | Profile | |
MBA MBA | CEO Council | Profile | |
Mukesh Rathi | Chief Digital and Information Officer | Profile |
About Dr Reddys Management Performance
The success or failure of an entity such as Dr Reddys Laboratories often depends on how effective the management is. Dr Reddys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RDY management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RDY management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.18 | 0.11 | |
Return On Capital Employed | 0.37 | 0.38 | |
Return On Assets | 0.16 | 0.09 | |
Return On Equity | 0.22 | 0.14 |
The data published in Dr Reddys' official financial statements usually reflect Dr Reddys' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dr Reddys Laboratories. For example, before you start analyzing numbers published by RDY accountants, it's critical to develop an understanding of what Dr Reddys' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Dr Reddys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dr Reddys' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dr Reddys' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dr Reddys Laboratories. Please utilize our Beneish M Score to check the likelihood of Dr Reddys' management manipulating its earnings.
Dr Reddys Workforce Analysis
Traditionally, organizations such as Dr Reddys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dr Reddys within its industry.Dr Reddys Manpower Efficiency
Return on Dr Reddys Manpower
Revenue Per Employee | 9.5M | |
Revenue Per Executive | 4.4B | |
Net Income Per Employee | 2.3M | |
Net Income Per Executive | 1.1B | |
Working Capital Per Employee | 4.6M | |
Working Capital Per Executive | 2.1B |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Dr Reddys Laboratories. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
CEOs Directory Screen CEOs from public companies around the world |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.76 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.